Fröhlich, Anne
Niebel, Dennis
Fietz, Simon
Egger, Eva
Buchner, Andrea
Sirokay, Judith
Landsberg, Jennifer http://orcid.org/0000-0001-8029-3883
Funding for this research was provided by:
DFG (EXC 1023)
Article History
Received: 24 January 2019
Accepted: 8 January 2020
First Online: 12 February 2020
Compliance with ethical standards
:
: Anne Fröhlich has received speaker’s honoraria or travel expense reimbursements from the following companies: Novartis, Bristol-Myers Squibb (BMS), Almirall, and Eli Lilly Pharma. Dennis Niebel has received speaker’s honoraria or travel expense reimbursements from the following companies: BMS, Novartis, GlaxoSmithKline (GSK), Celgene, and Merck Sharp & Dohme (MSD). Judith Sirokay received speaker’s honoraria from Novartis, BMS, MSD, and Roche. Jennifer Landsberg is a consultant/advisory board member of BMS, MSD, Novartis, and Roche, and has received speaker’s honoraria or travel expense reimbursements. No potential conflicts of interest were disclosed by all the other authors.
: Our study was approved by the Institutional Review Board (Vote No 187/16, Ethics commission, Faculty of Medicine, Bonn). Our study was conducted in accordance with the Helsinki Declaration of 1975.
: We obtained written informed consent from all patients or their authorized caregivers. Patients consented to the treatment and the use of their data, including photos, for research and publication.